Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87495 refers to a laboratory test designed to detect the infectious agent known as cytomegalovirus (CMV) through the analysis of nucleic acids, specifically DNA or RNA. Cytomegalovirus is a member of the herpesvirus family and is commonly transmitted from person to person via infected bodily fluids, which include blood, saliva, urine, semen, and breast milk. While CMV infection is prevalent in the general population, it typically manifests as a disease resembling mononucleosis primarily in individuals who are immunocompromised. In neonates, congenital or perinatal CMV infection can lead to severe health issues if symptoms are present at birth, or it may result in long-term complications such as hearing loss or vision impairment that may develop later in life. Additionally, pregnant women who contract CMV have the potential to transmit the virus to their fetus, which can have serious implications for the infant's health. The direct probe technique utilized in this test involves identifying a specific nucleic acid sequence, referred to as the target sequence, of the CMV if it is present in the biological sample. This process employs a probe that is labeled with either fluorescent or chemiluminescent markers. The sample undergoes treatment to release nucleic acids from the target organism, and the labeled probe selectively binds to the matching target sequence, forming a stable hybrid. This method is particularly effective because ribosomal RNA is often targeted, as it exists in numerous copies within most microorganisms, unlike genomic DNA, which may only have one or two copies. The test is distinct from the amplified probe technique, which significantly enhances assay sensitivity by exponentially multiplying the target sequence of CMV DNA or RNA into millions of copies, often utilizing polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR) for amplification. This allows for the identification of replicated sequences through labeled DNA probes, providing a robust method for detecting the presence of CMV in clinical samples.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87495 is indicated for the detection of cytomegalovirus (CMV) in various clinical scenarios. The following conditions may warrant the use of this test:

  • Immunocompromised Patients Individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplant recipients, or patients with HIV/AIDS, may require testing for CMV due to the increased risk of severe infection.
  • Congenital CMV Infection Newborns suspected of having congenital or perinatal CMV infection should be tested, especially if they exhibit symptoms at birth or are at risk for long-term complications such as hearing loss or vision impairment.
  • Pregnant Women Pregnant women who have been exposed to CMV or show signs of infection may be tested to assess the risk of transmission to the fetus.

2. Procedure

The procedure for CPT® Code 87495 involves several critical steps to ensure accurate detection of cytomegalovirus (CMV) nucleic acids. The following outlines the procedural steps:

  • Sample Collection A biological sample, such as blood, saliva, urine, or other bodily fluids, is collected from the patient. This sample serves as the source for nucleic acid extraction.
  • Nucleic Acid Extraction The collected sample undergoes treatment to release nucleic acids from any CMV present. This step is crucial as it prepares the sample for the subsequent detection process.
  • Probe Hybridization A labeled probe, which is designed to bind specifically to the target nucleic acid sequence of CMV, is introduced to the sample. The probe is either fluorescent or chemiluminescent, allowing for visualization of the hybridization event.
  • Formation of Stable Hybrid If CMV nucleic acids are present in the sample, the labeled probe will bind to the target sequence, forming a stable hybrid. This hybridization indicates the presence of CMV in the sample.
  • Detection The presence of the hybrid is then detected using appropriate methods that visualize the labeled probe, confirming the presence of CMV nucleic acids in the sample.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87495, the laboratory will analyze the results and report the findings. It is essential for healthcare providers to interpret the results in the context of the patient's clinical presentation and history. If CMV is detected, further clinical management may be necessary, especially for immunocompromised patients or newborns with congenital infection. Follow-up testing or additional diagnostic procedures may be recommended based on the initial findings. Healthcare providers should also consider counseling patients regarding the implications of a positive CMV test, particularly in pregnant women and parents of affected neonates.

Short Descr CYTOMEG DNA DIR PROBE
Medium Descr IADNA CYTOMEGALOVIRUS DIRECT PROBE TQ
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"